-
Heart failure with preserved ejection fraction: from mechanisms to therapiesLam CSP, Voors AA, de Boer RA et al. -
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID TrialW Zareba, JP Daubert, CA Beck et al.
-
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF TrialNassif ME, Windsor S, DEFINE-HF Investigators.
-
Ejection Fraction Pros and Cons: JACC State-of-the-Art ReviewTH Marwick
-
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin TM Emdin, A Aimo, G Vergaro et al.
-
AIM2-driven inflammasome activation in heart failureZ Onódi, M Ruppert, D Kucsera et al.
-
Cardiovascular Aging and Heart Failure: JACC Review Topic of the WeekF Triposkiadis, A Xanthopoulos, J Butler et al.
-
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced TrialSD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
